TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $230 | -71.7% | 25,768 | -51.3% | 0.00% | -100.0% |
| Q2 2023 | $812 | -39.5% | 52,871 | -11.5% | 0.00% | -50.0% |
| Q1 2023 | $1,343 | +10.2% | 59,731 | +3.1% | 0.00% | 0.0% |
| Q4 2022 | $1,219 | -99.9% | 57,951 | -0.0% | 0.00% | 0.0% |
| Q3 2022 | $1,429,000 | +36.5% | 57,977 | +34.2% | 0.00% | +100.0% |
| Q2 2022 | $1,047,000 | -6.3% | 43,218 | -0.3% | 0.00% | 0.0% |
| Q1 2022 | $1,117,000 | -16.9% | 43,339 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $1,344,000 | +40.9% | 43,284 | +10.0% | 0.00% | 0.0% |
| Q3 2021 | $954,000 | +29.1% | 39,339 | -22.3% | 0.00% | 0.0% |
| Q2 2021 | $739,000 | -36.1% | 50,654 | +9.4% | 0.00% | 0.0% |
| Q1 2021 | $1,156,000 | -8.4% | 46,300 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $1,262,000 | – | 46,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 875,221 | $19,683,720 | 7.52% |
| Deep Track Capital, LP | 6,147,268 | $138,252,057 | 5.68% |
| Kynam Capital Management, LP | 1,563,595 | $35,165,252 | 4.54% |
| GREAT POINT PARTNERS LLC | 1,003,000 | $22,557,470 | 4.43% |
| ARMISTICE CAPITAL, LLC | 7,148,000 | $160,758,520 | 2.32% |
| HighVista Strategies LLC | 121,834 | $2,740,047 | 2.23% |
| MPM BioImpact LLC | 313,642 | $7,053,809 | 1.83% |
| Sofinnova Investments, Inc. | 1,263,721 | $28,421,085 | 1.82% |
| Octagon Capital Advisors LP | 495,000 | $11,132,550 | 1.60% |
| SECTORAL ASSET MANAGEMENT INC | 358,613 | $8,065,206 | 1.55% |